CXR Biosciences, Wyeth Collaborate on $6.2M Drug Toxicity Marker Study | GenomeWeb
NEW YORK (GenomeWeb News) – The Scottish company CXR Biosciences said today it will work with the University of Dundee and Wyeth Pharmaceuticals in a £3 million ($6.2 million) collaboration to seek protein biomarkers that indicate the toxic effects of certain drugs.
 
CXR Bio said the three-year project is co-funded by the Technology Strategy Board and will be conducted in part by Wyeth scientists and by core lab staff at the Translational Medicine Research Center in Dundee.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.